JOSH TRENT

Work with Congress and the Administration to expand Medicaid coverage of whole genome sequencing for children with rare diseases.

Work with Congress and the Administration to ensure that the Orphan Drug Exclusion from eligibility for negotiation under the Medicare Drug Price Negotiation Program allows products to remain excluded so long as their FDA approved uses are exclusively for rare diseases.

Improvements to the 340B drug discount program.

Advocating for federal health care policies based on the National Academies 2020 report that will improve the lives of patients living with Sickle Cell Disease.

-Issues related to dual eligible beneficiaries including: -S.4635 - Comprehensive Care for Dual Eligible Individuals Act -S.4273 The Supporting States in Integrating Medicare and Medicaid Act of 2022 -S, 4264 Advancing Integration in Medicare and Medicaid Act -S. 3630 The Supporting Care for Dual Eligibles Act

GENOMIC ANSWERS FOR CHILDRENS HEALTH ALLIANCE (GACHA)

SAVE RARE TREATMENTS TASK FORCE

SICKLE CELL DISEASE PARTNERSHIP

340B WORKING TABLE

GENOMIC ANSWERS FOR CHILDRENS HEALTH ALLIANCE (GACHA)

THE DUAL ELIGIBLE COALITION

GENOMIC ANSWERS FOR CHILDRENS HEALTH ALLIANCE (GACHA)

SAVE RARE TREATMENTS TASK FORCE

SICKLE CELL DISEASE PARTNERSHIP

THE DUAL ELIGIBLE COALITION

340B WORKING TABLE

SICKLE CELL DISEASE PARTNERSHIP